Rapport Therapeutics (RAPP) investor relations material

Company overview and scientific approach

• Focus on precision neuroscience using receptor-associated proteins for targeted therapies.

• Lead program RAP-219 targets TARPγ-8 associated with the AMPA receptor.

• Demonstrated unprecedented results in focal onset seizures and ongoing expansion into other indications.

• Discovery portfolio aims to build a robust pipeline leveraging the same scientific foundation.

RAP-219 program updates and clinical rationale

• RAP-219 initially prioritized for epilepsy, then expanded to bipolar mania based on glutamate's role in mania.

• Imaging and literature support targeting corticolimbic network and TARPγ-8 in bipolar disorder.

• Anti-seizure medications have a history of efficacy in bipolar disorder, supporting the development path.

• Epilepsy results confirmed target engagement and a differentiated tolerability profile.

Unmet need and market opportunity in bipolar mania

• Bipolar I disorder affects about 1.6 million patients, with limited innovation in treatment.

• Current therapies include antipsychotics, lithium, and some anti-seizure medications, all with significant tolerability issues.

• Patients seek treatments that allow continued engagement in daily life, highlighting the need for better tolerability.

• RAP-219 aims to offer a novel mechanism with improved tolerability for long-term use.